Healthcare provider profile · identity verified

Michael Badlissi, M.D.

Internal Medicine · NEDERLAND, TX · NPI 1770710337

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	593	183
Amlodipine Besylate	Amlodipine Besylate	511	150
Gabapentin	Gabapentin	404	98
Levothyroxine Sodium	Levothyroxine Sodium	316	81
Pantoprazole Sodium	Pantoprazole Sodium	288	90
Metformin Hcl	Metformin Hcl	273	85
Hydrochlorothiazide	Hydrochlorothiazide	248	72
Furosemide	Furosemide	223	71
Lisinopril	Lisinopril	222	70
Losartan Potassium	Losartan Potassium	197	54
Metoprolol Succinate	Metoprolol Succinate	182	53
Montelukast Sodium	Montelukast Sodium	174	56
Omeprazole	Omeprazole	163	41
Methylprednisolone	Methylprednisolone	149	117
Trazodone Hcl	Trazodone Hcl	149	34
Carvedilol	Carvedilol	148	41
Potassium Chloride	Potassium Chloride	147	43
Celecoxib	Celecoxib	142	49
Meloxicam	Meloxicam	140	39
Glipizide	Glipizide	139	43
Ozempic	Semaglutide	133	19
Clopidogrel	Clopidogrel Bisulfate	126	49
Rosuvastatin Calcium	Rosuvastatin Calcium	124	43
Duloxetine Hcl	Duloxetine Hcl	120	26
Simvastatin	Simvastatin	119	32
Alprazolam	Alprazolam	109	17
Sertraline Hcl	Sertraline Hcl	109	26
Tamsulosin Hcl	Tamsulosin Hcl	107	31
Levofloxacin	Levofloxacin	100	80
Hydralazine Hcl	Hydralazine Hcl	96	22
Allopurinol	Allopurinol	92	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	92	19
Metoprolol Tartrate	Metoprolol Tartrate	92	31
Azithromycin	Azithromycin	90	62
Albuterol Sulfate Hfa	Albuterol Sulfate	88	20
Pravastatin Sodium	Pravastatin Sodium	88	25
Eliquis	Apixaban	81	23
Januvia	Sitagliptin Phosphate	81	21
Escitalopram Oxalate	Escitalopram Oxalate	80	20
Ondansetron Hcl	Ondansetron Hcl	80	29
Clonazepam	Clonazepam	77	suppressed
Lorazepam	Lorazepam	75	11
Zolpidem Tartrate	Zolpidem Tartrate	75	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	71	18
Atenolol	Atenolol	70	20
Tizanidine Hcl	Tizanidine Hcl	62	19
Clonidine Hcl	Clonidine Hcl	58	18
Fluticasone Propionate	Fluticasone Propionate	58	24
Doxazosin Mesylate	Doxazosin Mesylate	56	suppressed
Famotidine	Famotidine	56	20
Ketoconazole	Ketoconazole	56	23
Alendronate Sodium	Alendronate Sodium	55	18
Novolog Flexpen	Insulin Aspart	55	15
Pregabalin	Pregabalin	53	11
Ezetimibe	Ezetimibe	49	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	48	15
Nystatin	Nystatin	47	23
Donepezil Hcl	Donepezil Hcl	46	13
Fluconazole	Fluconazole	45	23
Meclizine Hcl	Meclizine Hcl	45	16
Prednisone	Prednisone	45	24
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	44	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	39
Paroxetine Hcl	Paroxetine Hcl	42	11
Synthroid	Levothyroxine Sodium	40	suppressed
Glipizide Er	Glipizide	39	11
Sucralfate	Sucralfate	39	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Lovastatin	Lovastatin	36	suppressed
Nifedipine Er	Nifedipine	36	suppressed
Ramipril	Ramipril	36	suppressed
Spironolactone	Spironolactone	36	14
Olmesartan Medoxomil	Olmesartan Medoxomil	34	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Temazepam	Temazepam	33	suppressed
Irbesartan	Irbesartan	32	suppressed
Lactulose	Lactulose	32	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Xarelto	Rivaroxaban	31	suppressed
Benazepril Hcl	Benazepril Hcl	30	suppressed
Humalog Kwikpen U-100	Insulin Lispro	30	suppressed
Hydrocortisone	Hydrocortisone	30	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	16
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	30	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Metolazone	Metolazone	28	suppressed
Glimepiride	Glimepiride	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Methocarbamol	Methocarbamol	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Metformin Hcl Er	Metformin Hcl	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	22
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Minoxidil	Minoxidil	23	suppressed
Nebivolol Hcl	Nebivolol Hcl	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	13
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	22	suppressed
Cefdinir	Cefdinir	22	14
Diazepam	Diazepam	22	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Digoxin	Digoxin	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	17	suppressed
Clindamycin Hcl	Clindamycin Hcl	17	14
Farxiga	Dapagliflozin Propanediol	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Torsemide	Torsemide	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Dutasteride	Dutasteride	16	suppressed
Humulin N	Insulin Nph Human Isophane	16	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Ssd	Silver Sulfadiazine	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	14
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Labetalol Hcl	Labetalol Hcl	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Albuterol Sulfate	Albuterol Sulfate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Clonidine	Clonidine	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	14	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Oxcarbazepine	Oxcarbazepine	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Colchicine	Colchicine	13	suppressed
Constulose	Lactulose	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Megestrol Acetate	Megestrol Acetate	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	12	suppressed
Finasteride	Finasteride	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Indapamide	Indapamide	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Scopolamine	Scopolamine	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Ursodiol	Ursodiol	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Enulose	Lactulose	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error